NCT03783377View on ClinicalTrials.gov

Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)

PHASE1CompletedINTERVENTIONAL
Enrollment

112

Participants

Timeline

Start Date

March 8, 2019

Primary Completion Date

February 11, 2021

Study Completion Date

February 11, 2021

Conditions
HypertriglyceridemiaFamilial Chylomicronemia
Interventions
DRUG

ARO-APOC3

single or multiple doses of ARO-APOC3 by subcutaneous (sc) injections

DRUG

sterile normal saline (0.9% NaCl)

calculated volume to match active treatment

Trial Locations (10)

1010

Auckland Clinical Studies Limited, Grafton

2025

Middlemore Hospital, Papatoetoe

2050

Royal Prince Alfred Hospital, Camperdown

5000

Royal Adelaide Hospital, Adelaide

6009

Linear Clinical Research, Perth

8011

Lipid & Diabetes Research Group, Christchurch

Unknown

University of the Sunshine Coast Clinical Trial Centre, Sippy Downs

N6A 5B7

Robarts Research Institute, London

G7H 7K9

Ecogene-21, Chicoutimi

H2W 1R7

Institute de Recherches Cliniques de Montreal, Montreal

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY